Form 4: Gabrielle Sulzberger, Eli Lilly & Co Director, Reports Stock Acquisition

Director Gabrielle Sulzberger reports acquiring 6.679 shares of Eli Lilly & Co common stock at $742.35 per share through the Lilly Directors' Deferral Plan.

Summary

• On January 21, 2025, Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 6.679 shares of common stock at a price of $742.35 per share.
• The acquisition was made through the Lilly Directors' Deferral Plan, where shares are deferred in lieu of cash compensation.
• These shares will be settled in common stock following Sulzberger's separation from service.
• Following the transaction, Sulzberger directly owns 2,539.61 shares of Eli Lilly & Co common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The director's stock acquisition suggests confidence in the company, but it's a routine transaction.

Positives

• The director's participation in the Lilly Directors' Deferral Plan demonstrates confidence in the company's future.

Future Outlook

The shares acquired are deferred and will be settled in common stock following the reporting person's separation from service.

Industry Context

This filing is a routine disclosure of a director's stock acquisition, which is common among publicly traded companies. It reflects participation in a deferred compensation plan, a typical practice for aligning director interests with shareholder value.

Comparison to Industry Standards

• Director stock ownership is a common practice across publicly traded companies, including pharmaceutical giants like Pfizer (PFE) and Johnson & Johnson (JNJ).
• Deferred compensation plans, similar to the Lilly Directors' Deferral Plan, are frequently used to incentivize and retain board members.
• The level of stock ownership and acquisition by directors is often compared to industry peers to gauge alignment with shareholder interests.

Stakeholder Impact

• The director's stock acquisition can positively influence shareholder sentiment, as it signals confidence in the company's prospects.

Key Dates